Adcendo is a clinical-stage biotechnology company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancers with significant unmet medical needs. It designs these therapies by combining insights into target biology with specialized linker and payload technologies to deliver drugs directly to cancer cells. The company advances a pipeline of drug candidates aimed at solid tumors, including programs that target specific receptors associated with cancer progression. Its research approach emphasizes translating scientific discoveries into clinically differentiated treatments through structured development plans. Adcendo also collaborates with scientific experts, clinical partners, and technology providers to support the progression of its therapeutic programs.